Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study
Sign Up to like & getrecommendations! Published in 2022 at "BMC Cancer"
DOI: 10.1186/s12885-022-09173-4
Abstract: Background Vascular endothelial growth factor (VEGF) plays a role in the tumor microenvironment. Sorafenib, which inhibits the VEGF pathway, has an immune-modulation function but lacks substantial clinical data. This study aims to explore the efficacy… read more here.
Keywords: propensity score; study; advanced hepatocellular; anti combined ... See more keywords
Penpulimab (Anti-PD-1) combined with anlotinib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Updated results from a phase Ib/II study.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.3_suppl.306
Abstract: 306Background: Combined therapy of an immune checkpoint inhibitor with a targeted antiangiogenic agent had been proved to be effective for the treatment of uHCC. Penpulimab was engineered to elimin... read more here.
Keywords: therapy; combined anlotinib; penpulimab anti; penpulimab ... See more keywords